"Protein Kinase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that inhibit PROTEIN KINASES.
Descriptor ID |
D047428
|
MeSH Number(s) |
D27.505.519.389.755
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Protein Kinase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Protein Kinase Inhibitors".
This graph shows the total number of publications written about "Protein Kinase Inhibitors" by people in this website by year, and whether "Protein Kinase Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2006 | 0 | 2 | 2 |
2009 | 0 | 1 | 1 |
2010 | 1 | 1 | 2 |
2012 | 0 | 1 | 1 |
2015 | 1 | 1 | 2 |
2018 | 2 | 0 | 2 |
2019 | 1 | 0 | 1 |
2020 | 3 | 0 | 3 |
2021 | 0 | 1 | 1 |
2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Protein Kinase Inhibitors" by people in Profiles.
-
Mast cell deficiency prevents BCR::ABL1 induced splenomegaly and cytokine elevation in a CML mouse model. Leukemia. 2023 07; 37(7):1474-1484.
-
Secondary resistance to anti-EGFR therapy by transcriptional reprogramming in patient-derived colorectal cancer models. Genome Med. 2021 07 16; 13(1):116.
-
BCR-ABL tyrosine kinase inhibitors promote pathological changes in dilator phenotype in the human microvasculature. Microcirculation. 2020 10; 27(7):e12625.
-
Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany. Breast. 2020 Dec; 54:88-95.
-
Therapeutic inhibition of Fc?RIIb signaling targets leukemic stem cells in chronic myeloid leukemia. Leukemia. 2020 10; 34(10):2635-2647.
-
Infliximab therapy together with tyrosine kinase inhibition targets leukemic stem cells in chronic myeloid leukemia. BMC Cancer. 2019 Jul 04; 19(1):658.
-
Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial. Leukemia. 2018 07; 32(7):1657-1669.
-
Targeting HSP90 dimerization via the C terminus is effective in imatinib-resistant CML and lacks the heat shock response. Blood. 2018 07 19; 132(3):307-320.
-
Infection Exposure is a Causal Factor in B-cell Precursor Acute Lymphoblastic Leukemia as a Result of Pax5-Inherited Susceptibility. Cancer Discov. 2015 Dec; 5(12):1328-43.
-
RNAi profiling of primary human AML cells identifies ROCK1 as a therapeutic target and nominates fasudil as an antileukemic drug. Blood. 2015 Jun 11; 125(24):3760-8.